{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:47:42Z","timestamp":1761864462459,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejso.2022.09.010","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T22:13:03Z","timestamp":1663625583000},"page":"2308-2314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The changing role for extended resections in an era of advanced radiotherapy techniques and novel therapies in gynaecological malignancy"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-4890","authenticated-orcid":false,"given":"R.D.","family":"McBain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-0755","authenticated-orcid":false,"given":"M.F.G.","family":"McGauran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-0881","authenticated-orcid":false,"given":"P.Y.L.","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.M.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2011","series-title":"The annals of extreme surgery","author":"Lerner","key":"10.1016\/j.ejso.2022.09.010_bib1"},{"key":"10.1016\/j.ejso.2022.09.010_bib2","doi-asserted-by":"crossref","unstructured":"Lampe B, Luengas Wurzinger V, Weitz J, Roth S, Rawert F, Schuler E, Classen-von Spee S, Fix N, Baransi S, Dizdar A et\u00a0al. Opportunities and Limitations of Pelvic Exenteration Surgery. Cancers. 21; 13: 6162. https:\/\/doi.org\/10.3390\/cancers13246162.","DOI":"10.3390\/cancers13246162"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2005.05.034","article-title":"Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidty analysis of the 45-year experience at UCLA","volume":"99","author":"Berek","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2022.09.010_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ygyno.2005.10.011","article-title":"Total pelvic exenteration: the albert einstein college of medicine\/montefiore medical center experience (1987 to 2003)","volume":"101","author":"Goldberg","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2009.03.029","article-title":"Pelvic exenteration: ten-year experience at the European institute of oncology in milan","volume":"114","author":"Maggioni","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2011.03.003","article-title":"Pelvic exenteration in gynecologic oncology: a single institution study over 20 years","volume":"122","author":"Benn","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2010.11.044","article-title":"Pelvic exenteration in the age of modern chemoradiation","volume":"121","author":"McLean","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib8","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ejso.2012.07.002","article-title":"Prognostic factors in pelvic exenteration for gynecological malignancies","volume":"38","author":"Baiocchi","year":"2012","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/IGC.0000000000000011","article-title":"Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients","volume":"24","author":"Chiantera","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00404-019-05154-4","article-title":"Pelvic exenteration as ultimate ratio for gynecologic cancers; single centre analyses of 37 cases","volume":"300","author":"De Gregorio","year":"2019","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IGC.0b013e31824eb8cd","article-title":"Pelvic exenterations for gynecological malignancies: a study of 36 cases","volume":"22","author":"Kaur","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2022.09.010_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ygyno.2012.03.001","article-title":"Indications and long-term clinical outcomes in 282 patients with eplvic exenteration for advanced or recurrent cervical cancer","volume":"125","author":"Schmidt","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10147-013-0534-9","article-title":"Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer","volume":"19","author":"Tanaka","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2022.09.010_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3802\/jgo.2012.23.4.242","article-title":"Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea","volume":"23","author":"Yoo","year":"2012","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib15","series-title":"Superradical hysterectomy for cervical cancer as an alternative to the usual Okabayashi-type radical hysterectomy. Precision surgery in Obstetrics and Gynecology","first-page":"S108","author":"Mandai","year":"2021"},{"key":"10.1016\/j.ejso.2022.09.010_bib16","series-title":"Complete excision of the pelvic viscera for advanced carcinoma","first-page":"177","author":"Brunschwig","year":"1948"},{"issue":"417","key":"10.1016\/j.ejso.2022.09.010_bib17","first-page":"1305","article-title":"Pelvic exenteration combined with resection of segments of bony pelvis","volume":"65","author":"Brunschwig","year":"1969","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1525-1438.2007.01140.x","article-title":"Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery","volume":"18","author":"Caceres","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2022.09.010_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2022.03.002","article-title":"Extended pelvic resection for gynaecological malignancies: a review of out-of-the-box surgery","volume":"165","author":"Daix","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2022.09.010_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2020.01.029","article-title":"Trends in HPV-dependent and HPV-independent vulvar cancers: the changing face of vulvar squamous cell carcinoma","volume":"157","author":"Eva","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib21","first-page":"141","article-title":"Re-irradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience","volume":"24","author":"Mabuchi","year":"2014","journal-title":"Int J Green Comput"},{"key":"10.1016\/j.ejso.2022.09.010_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/bjc.2013.521","article-title":"Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC sudy?","volume":"109","author":"Takano","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2022.09.010_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2011.05.020","article-title":"Surgical cytoreduction in Stage IV endometrioid endometrial carcinoma","volume":"122","author":"Shih","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13304-015-0340-1","article-title":"Surgical treatment of high stage endometrial cancer: current perspectives","volume":"68","author":"Vitale","year":"2016","journal-title":"Updates Surg"},{"key":"10.1016\/j.ejso.2022.09.010_bib25","series-title":"Long term survival after pelvic exenteration and total vaginecomty for recurrent endometrial carcinoma with metastatic inguinal nodes at the time of surgery","first-page":"39","volume":"vol. 19","author":"Margolis","year":"2017"},{"key":"10.1016\/j.ejso.2022.09.010_bib26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.brachy.2017.07.007","article-title":"MR versus CT based high dose rate interstitial brachytherapy for vaginal recurrence of endometrial carncer","volume":"16","author":"Kamran","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ejso.2022.09.010_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2011.09.022","article-title":"Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma","volume":"124","author":"Podzielinski","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/gyno.1996.0123","article-title":"Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium","volume":"61","author":"Fishman","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5114\/jcb.2017.67755","article-title":"Outcome of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer","volume":"9","author":"Sekii","year":"2017","journal-title":"J\u00a0Contemp Brachytherapy"},{"key":"10.1016\/j.ejso.2022.09.010_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13014-016-0622-x","article-title":"Outcomes of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT)","volume":"11","author":"Arians","year":"2016","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2022.09.010_bib31","first-page":"418","article-title":"Salvage curative-intent reirradiation stereotactic body radiation therapy for isolated pelvic and\/or paraortic recurrences of gynecologic malignancies","volume":"9","author":"Ling","year":"2019","journal-title":"PRO"},{"key":"10.1016\/j.ejso.2022.09.010_bib32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.ijrobp.2017.08.027","article-title":"Reirradiation using permanent interstitial brachytherapy: a potentially durable technique for salvaging recurrent pelvic malignancies","volume":"99","author":"Feddock","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2022.09.010_bib33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ygyno.2014.02.015","article-title":"Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies","volume":"133","author":"Wooten","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ygyno.2011.09.014","article-title":"Exenteration in the treatment of stage III\/IV vulvar cancer","volume":"124","author":"Former","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/gyno.1995.1211","article-title":"Pelvic exenteration for primary and recurrent vulvar cancer","volume":"58","author":"Miller","year":"1995","journal-title":"Gynecol Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ejso.2022.09.010_bib36","first-page":"S97","article-title":"Cancer of the vagina","volume":"119","author":"Hacker","year":"2012","journal-title":"Int J Green Comput"},{"key":"10.1016\/j.ejso.2022.09.010_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.radonc.2018.03.003","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer","volume":"127","author":"Cibula","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment nad follow up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial cancer","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib40","first-page":"92","article-title":"Vulvar cancer, version 1.2017","volume":"15","author":"Koh","year":"2017","journal-title":"J\u00a0NCCN"},{"issue":"4","key":"10.1016\/j.ejso.2022.09.010_bib41","first-page":"832","article-title":"ESGO Guidelines for the management of patients with vulvar cancer","volume":"27","author":"Oonk","year":"2017","journal-title":"Int J Green Comput"},{"key":"10.1016\/j.ejso.2022.09.010_bib42","first-page":"201","article-title":"Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer","volume":"23","author":"Saito","year":"2018","journal-title":"Int J Green Comput"},{"issue":"7","key":"10.1016\/j.ejso.2022.09.010_bib43","first-page":"1534","article-title":"ESGO guidelines for ovarian cancer surgery","volume":"27","author":"Querleu","year":"2017","journal-title":"Int J Green Comput"},{"key":"10.1016\/j.ejso.2022.09.010_bib44","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected time frame until cervical elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Health"},{"year":"2021","series-title":"Cervical Cancer Elimination Progress Report: Australia's progress towards the elimination of cervical cancer as a public health problem","key":"10.1016\/j.ejso.2022.09.010_bib45"},{"issue":"3","key":"10.1016\/j.ejso.2022.09.010_bib46","first-page":"CD002225","article-title":"Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix","volume":"20","author":"Green","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejso.2022.09.010_bib47","first-page":"CD008285","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis","volume":"1","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib48","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01","volume":"22","author":"Eifel","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2022.09.010_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2022.09.010_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.radonc.2016.03.020","article-title":"Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: analysis from the retroEMBRACE study","volume":"120","author":"Fokdal","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib51","first-page":"48","article-title":"The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies","volume":"9","author":"Potter","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib52","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2019.12.019","article-title":"Ring versus ovoids and intracavitary versus intracavitary-interstitial applicators in cervical cancer brachytherapy: results from the EMBRACE I study","volume":"106","author":"Serban","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.ejso.2022.09.010_bib53","first-page":"1","article-title":"Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy","volume":"15","author":"Leung","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ygyno.2020.10.001","article-title":"Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers","volume":"159","author":"Reshko","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2022.09.010_bib55","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2014.06.034","article-title":"Overall survival after pelvic exenteration for gynaecologic malignancy","volume":"134","author":"Westin","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/SLA.0000000000003533","article-title":"Pelvic exenteration for advanced nonrectal pelvic malignancy","volume":"270","author":"PelvExCollaborative","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2022.09.010_bib57","doi-asserted-by":"crossref","unstructured":"Cibula D, Lednicky S, Hoschlova E, Slama J, Wiesnerova M, Mitasa P, Matejovsky Z, Scheiderova M, Dundr P, Nemejcova K, Burgetova A, Zamechnik L, Vocka M, Kocian R, Fruhauf F, Dostalex L, Fischerova D, Borcinova M. Quality of life after extended pelvic exenterations. Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2022.04.022.","DOI":"10.1016\/j.ygyno.2022.04.022"},{"year":"2020","series-title":"Global Strategy to accelerate the elimination of cervical cancer as a public health problem","key":"10.1016\/j.ejso.2022.09.010_bib58"},{"issue":"2","key":"10.1016\/j.ejso.2022.09.010_bib59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0002-9378(99)70204-8","article-title":"Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecologic malignancies","volume":"180","author":"Hockel","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejso.2022.09.010_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0090-8258(03)00502-X","article-title":"Laterally extended endopelvic resection: novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic sidewall","volume":"91","author":"Hockel","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib61","doi-asserted-by":"crossref","unstructured":"Ling DC, Vargo JA, Glaser SM et\u00a0al. Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer. Gynecol Oncol; 152: 581-586.","DOI":"10.1016\/j.ygyno.2018.12.022"},{"issue":"1","key":"10.1016\/j.ejso.2022.09.010_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1245\/ASO.2004.03.053","article-title":"Composite pelvic exenteration: is it worthwhile?","volume":"11","author":"Lopez","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib63","doi-asserted-by":"crossref","unstructured":"Slomovitz BM, Coleman RL. Invasive cancer of the vagina. In: Di Saia PJ, Creasman WT (eds) Clinical gynecologic oncology, eighth ed. Elsevier Saunders, Philadelphia pp 245-259.","DOI":"10.1016\/B978-0-323-07419-3.00009-6"},{"issue":"3","key":"10.1016\/j.ejso.2022.09.010_bib64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2016.03.011","article-title":"Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study","volume":"120","author":"Sturdza","year":"2016","journal-title":"Radiother Oncol"},{"issue":"36","key":"10.1016\/j.ejso.2022.09.010_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1\u2013positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"37","key":"10.1016\/j.ejso.2022.09.010_bib66","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"10","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2022.09.010_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejso.2022.09.010_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejso.2022.09.010_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5501","article-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)","volume":"37","author":"Antill","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2022.09.010_bib70","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejso.2022.09.010_bib71","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejso.2022.09.010_bib72","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2022.09.010_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322006771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322006771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:43:38Z","timestamp":1760060618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798322006771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0748798322006771"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2022.09.010","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing role for extended resections in an era of advanced radiotherapy techniques and novel therapies in gynaecological malignancy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2022.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}